Intramuscular arteether for treating severe malaria

Simple item page
dc.contributor.authorAfolabi, B.B.
dc.contributor.authorOkoromah, C.N
dc.date.accessioned2020-11-17T07:45:12Z
dc.date.available2020-11-17T07:45:12Z
dc.date.issued2004
dc.descriptionStaff Publicationsen_US
dc.description.abstractAbstract Background: Quinine and artemisinin drugs are used in severe malaria, but quinine resistance is increasing. Arteether is a recently developed artemisinin derivative that is oil soluble, has a long elimination half life, and is more stable than other derivatives. Objectives: To compare intramuscular arteether with other antimalarial drugs to treat severe malaria. Search strategy: We searched the Cochrane Infectious Diseases Group Specialized Register (August 2004), CENTRAL (The Cochrane Library Issue 3, 2004), MEDLINE (1966 to August 2004), EMBASE (1980 to August 2004), U.S. National Library of Medicine (NLM) Gateway (1953 to 1965), Web Science Citation (1981 to August 2004), LILACS (August 2004), Google search engine (August 2004), conference proceedings, and reference lists. We also contacted researchers, organizations, and pharmaceutical companies to help identify trials. Selection criteria: Randomized and quasi-randomized controlled trials of intramuscular arteether in adults and children with severe malaria. Data collection and analysis: We independently assessed the methodological quality of the trials and extracted data, and analysed data using Review Manager 4.2. Main results: Two small trials (n = 194) met the inclusion criteria. Both trials compared arteether with quinine in children with cerebral malaria and reported on similar outcomes. There was no statistically significant difference in the number of deaths (relative risk 0.75, 95% confidence interval 0.43 to 1.30; n = 194, 2 trials), neurological complications (relative risk 1.18, 95% confidence interval 0.31 to 4.46; n = 58, 1 trial), or other outcomes including time to regain consciousness, parasite clearance time, and fever clearance time. The meta-analyses lack statistical power to detect important differences. Reviewers' conclusions: More trials with a larger number of participants are needed before a firm conclusion about the efficacy and safety of arteether can be reached.en_US
dc.identifier.citationAfolabi, B.B., & Okoromah CN. Intramuscular arteether for treating severe malaria. Cochrane Database Syst Rev. 2004 Oct 18;(4)en_US
dc.identifier.other10.1002/14651858
dc.identifier.urihttps://ir.unilag.edu.ng/handle/123456789/8938
dc.language.isoenen_US
dc.publisherCochrane Database Syst Reven_US
dc.subjectQuinine resistanceen_US
dc.subjectArteetheren_US
dc.subjectMalariaen_US
dc.subjectAntimalaria drugsen_US
dc.titleIntramuscular arteether for treating severe malariaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
AFOLABI Intramuscular Arteether for treating severe Malaria.pdf
Size:
177.65 KB
Format:
Adobe Portable Document Format
Description:
Cochrane review
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Obstetrics and Gynaecology- Scholarly Publications